Cargando…

Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy

BACKGROUND: A substantial number of patients will develop further biochemical progression after radical prostatectomy (RP) and salvage radiotherapy (sRT). Recently published data using prostate-specific membrane antigen ligand positron emission tomography (PSMA - PET) for re-staging suggest that tho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oehus, Ann-Kathrin, Kroeze, Stephanie G. C., Schmidt-Hegemann, Nina-Sophie, Vogel, Marco M. E., Kirste, Simon, Becker, Jessica, Burger, Irene A., Derlin, Thorsten, Bartenstein, Peter, Eiber, Matthias, Mix, Michael, la Fougère, Christian, Belka, Claus, Combs, Stephanie E., Grosu, Anca-Ligia, Müller, Arndt-Christian, Guckenberger, Matthias, Christiansen, Hans, Henkenberens, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191762/ https://www.ncbi.nlm.nih.gov/pubmed/32349700 http://dx.doi.org/10.1186/s12885-020-06883-5

Ejemplares similares

Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [(68)Ga]PSMA-PET-guided metastasis-directed therapy
por: Vogel, Marco M. E., et al.
Publicado: (2020)

Combining (68)Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study
por: Kirste, Simon, et al.
Publicado: (2021)

Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy
por: Spohn, Simon K. B., et al.
Publicado: (2023)

Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET–Based Salvage Radiotherapy for Recurrent Prostate Cancer
por: Zamboglou, Constantinos, et al.
Publicado: (2023)

PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml
por: Solomonidou, Nantia, et al.
Publicado: (2023)

The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy—a multicenter retrospective analysis
por: Spohn, Simon K. B., et al.
Publicado: (2022)

A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa
por: Schmidt-Hegemann, Nina-Sophie, et al.
Publicado: (2021)

Feasibility and Outcome of PSMA-PET-Based Dose-Escalated Salvage Radiotherapy Versus Conventional Salvage Radiotherapy for Patients With Recurrent Prostate Cancer
por: Vogel, Marco M. E., et al.
Publicado: (2021)

Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy
por: Rogowski, Paul, et al.
Publicado: (2021)

PSMA-positive nodal recurrence in prostate cancer: Salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis
por: Schmidt-Hegemann, Nina-Sophie, et al.
Publicado: (2020)

PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives
por: Zschaeck, Sebastian, et al.
Publicado: (2018)

Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis
por: Schmidt Hegemann, Nina-Sophie, et al.
Publicado: (2020)

Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy
por: Henkenberens, Christoph, et al.
Publicado: (2020)

Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy
por: Schmidt-Hegemann, Nina-Sophie, et al.
Publicado: (2018)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

Impact of (68)Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy
por: Bluemel, Christina, et al.
Publicado: (2016)

Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study
por: Dewes, Sabrina, et al.
Publicado: (2016)

Can PSMA PET/CT help in dose-tailoring in post-prostatectomy radiotherapy?
por: Champion, Ambroise, et al.
Publicado: (2023)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

The Prognostic Value of Liquid Biopsies for Benefit of Salvage Radiotherapy in Relapsed Oligometastatic Prostate Cancer
por: Bogdanova, Natalia V., et al.
Publicado: (2022)

Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery
por: Guckenberger, Matthias, et al.
Publicado: (2020)

Local control and possibility of tailored salvage after hypofractionated stereotactic radiotherapy of the cavity after brain metastases resection
por: Bilger, Angelika, et al.
Publicado: (2018)

Adjuvant versus early salvage radiotherapy: outcome of patients with prostate cancer treated with postoperative radiotherapy after radical prostatectomy
por: Vogel, Marco M. E., et al.
Publicado: (2019)

Risk Factors for Biochemical Recurrence After PSMA-PET-Guided Definitive Radiotherapy in Patients With De Novo Lymph Node-Positive Prostate Cancer
por: Spohn, Simon K.B., et al.
Publicado: (2022)

Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis
por: Hegemann, Nina-Sophie, et al.
Publicado: (2017)

Multicenter analysis of stereotactic radiotherapy of the resection cavity in patients with brain metastases
por: Combs, Stephanie E., et al.
Publicado: (2018)

Patient-Reported and Oncological Outcomes of Salvage Therapies for PSMA-Positive Nodal Recurrent Prostate Cancer: Real-Life Experiences and Implications for Future Trial Design
por: Kretschmer, Alexander, et al.
Publicado: (2021)

Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis
por: Ziegler, Johanna S., et al.
Publicado: (2020)

Optimal timing of salvage radiotherapy for biochemical recurrence after radical prostatectomy: is ultra-early salvage radiotherapy beneficial?
por: Taguchi, Satoru, et al.
Publicado: (2016)

Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer
por: Jilg, Cordula A, et al.
Publicado: (2014)

Repeated Courses of Radiosurgery for New Brain Metastases to Defer Whole Brain Radiotherapy: Feasibility and Outcome With Validation of the New Prognostic Metric Brain Metastasis Velocity
por: Fritz, Corinna, et al.
Publicado: (2018)

Detection of local recurrent prostate cancer after radical prostatectomy in terms of salvage radiotherapy using dynamic contrast enhanced-MRI without endorectal coil
por: Rischke, Hans Christian, et al.
Publicado: (2012)

Pelvic salvage (SBRT) radiotherapy based on (68)Ga-PSMA PET/CT: About a case
por: Slaoui, A., et al.
Publicado: (2019)

A survey among German-speaking radiation oncologists on PET-based radiotherapy of prostate cancer
por: Vogel, Marco M. E., et al.
Publicado: (2021)

Impact of a low FODMAP diet on the amount of rectal gas and rectal volume during radiotherapy in patients with prostate cancer – a prospective pilot study
por: Schaefer, Christian, et al.
Publicado: (2020)

Editorial: Stereotactic body radiotherapy for lung cancer
por: Liu, An, et al.
Publicado: (2023)

Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy
por: Schmidt-Hegemann, Nina-Sophie, et al.
Publicado: (2017)

Salvage radiotherapy with or without hormone therapy: for whom and when?
por: Carrie, Christian
Publicado: (2017)

The Utility of 68Ga-PSMA PET/CT in Decisions Regarding Administering Salvage Radiotherapy to Men with Prostate Cancer
por: Ben Shimol, Jennifer, et al.
Publicado: (2022)

Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT)
por: Habl, Gregor, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_94p6ff9gn5nri8qu3ut213pn7p